ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 975

Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study

KA Casey1, WI White1, Nickie L. Seto2, Martin Playford3, MA Smith1, P Carlucci2, B Yu4, L Wang5, G Illei4, Nehal Mehta3 and Mariana J. Kaplan2, 1MedImmune, Gaithersburg, MD, 2NIAMS, Bethesda, MD, 3NHLBI, Bethesda, MD, 4MedImmune, Gaithersberg, MD, 5AstraZeneca, Gaithersburg, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cholesterol, inflammation and interferons, Neutrophil Extracellular Traps, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S110 ACR Abstract: SLE–Clinical I: Clinical Trials (970–975)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Cardiovascular disease is a leading cause of death for patients with systemic lupus erythematosus (SLE), and the disease is widely known to feature premature atherosclerosis promoted by immune dysregulation. Neutrophil extracellular traps (NETs) can induce endothelial dysfunction and promote inflammatory events. Furthermore, sources of reactive oxygen species released during NET formation promote oxidized high-density lipoprotein, leading to deficient cholesterol efflux capacity (CEC). Type I interferons (IFNs) stimulate NET formation and inhibit vascular repair. Anifrolumab is a fully human, IgG1 κ monoclonal antibody that binds to IFNAR1 and blocks signaling of all type I IFNs. Thus, anifrolumab may decrease mechanisms of vascular damage in SLE. We evaluated the ability of anifrolumab to reduce in-vivo NET formation and improve CEC relative to standard of care (SOC) in MUSE.1

Methods: Baseline IFN gene signature (IFNGS) test status (high/low) of MUSE patients was determined as described.1 All patients satisfied the ACR classification criteria for lupus.1 Plasma samples from fasting patients (n=190) were obtained at days 1 and 365 of the MUSE study. Plasma MPO-, HNE- and CitH3-DNA NET complexes were quantified by ELISAs in the MUSE and healthy donor (HD) samples (n=20) as described.2 Wilcoxon rank-sum test assessed differences between groups. Post-treatment samples from the 300 mg anifrolumab (n=73) and placebo (n=52) groups were compared with baseline samples. Significance of change from baseline was determined using Wilcoxon signed-rank test. CEC was tested as described.3 Reproducibility of the CEC assay was assessed using percent coefficient of variation (CV) from the analysis of variance (ANOVA). SLE patients with defective baseline CEC were identified as those with CEC < (the HD mean value – 2 standard deviations) in the same testing run.

Results: All 3 neutrophil NET complexes (NNCs) were elevated in SLE patients (p<0.01) and were significantly enriched in IFN test–high patients (p<0.05). Anifrolumab significantly decreased all 3 NNCs at Day 365 vs. Day 1 (p≤0.05), whereas in the placebo group, complexes did not change or increased. The repeatability of the CEC assay was 7.5% across 2 days of testing for a subset of 26 baseline samples, and longitudinal changes in steroid dosage for the placebo group did not affect CEC. Greater baseline NET complex levels significantly correlated with poor baseline CEC (p<0.05). Anifrolumab significantly increased CEC in IFNGS test–high patients with defective CEC at baseline (p<0.001), whereas no significant changes occurred in the placebo group.

Conclusion: Circulating NNCs were significantly elevated in patients with moderate to severe SLE compared with HDs. Anifrolumab decreased circulating NNCs. Although changes in steroid dosages during MUSE did not affect CEC, anifrolumab significantly improved CEC. This work supports continued assessment of anifrolumab effects on vascular diseases and endothelial damage in SLE.

1Furie R, et al. Arthritis Rheumatol. 2017;69:376–86.

2Demoruelle MK, et al. Arthritis Rheumatol. 2017;69:1165–75.

3Salahuddin T, et al. Eur Heart J. 2015;36:2662–5.


Disclosure: K. Casey, AstraZeneca, 1,MedImmune, 3; W. White, AstraZeneca, 1,MedImmune, 3; N. L. Seto, None; M. Playford, None; M. Smith, AstraZeneca, 1,MedImmune, 3; P. Carlucci, None; B. Yu, AstraZeneca, 1,MedImmune, 3; L. Wang, AstraZeneca, 1,MedImmune, 3; G. Illei, AstraZeneca, 1,MedImmune, 5; N. Mehta, AbbVie, Novartis, Janssen, and Celgene, 2; M. J. Kaplan, MedImmune, 2.

To cite this abstract in AMA style:

Casey K, White W, Seto NL, Playford M, Smith M, Carlucci P, Yu B, Wang L, Illei G, Mehta N, Kaplan MJ. Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/alteration-of-vascular-inflammatory-markers-in-sle-by-anifrolumab-in-the-phase-iib-muse-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/alteration-of-vascular-inflammatory-markers-in-sle-by-anifrolumab-in-the-phase-iib-muse-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology